RADIUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of RDUS and Encourages Investors to Contact the Firm
24 juin 2022 23h29 HE
|
Bragar Eagel & Squire
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting
13 sept. 2019 18h03 HE
|
Radius Health Inc.
WALTHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced it will present five posters, including results from a real-world study on patient experience,...
Radius Health to Present Two Posters at AACE 2019 Annual Meeting
17 avr. 2019 08h00 HE
|
Radius Health Inc.
WALTHAM, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
23 mars 2019 12h45 HE
|
Radius Health Inc.
-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies...
Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting
24 sept. 2018 08h00 HE
|
Radius Health Inc.
WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing...
Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting
17 mars 2018 12h30 HE
|
Radius Health Inc.
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection
12 mars 2018 16h30 HE
|
Radius Health Inc.
WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
LAVOIE GROUP WINS SILVER AWARD IN THE 26th ANNUAL MERCURY EXCELLENCE AWARDS COMPETITION FOR REBRANDING RADIUS HEALTH, INC.
25 mars 2013 14h15 HE
|
LaVoie Health Science
Cambridge, MA, March 25, 2013 (GLOBE NEWSWIRE) -- LaVoie
Strategic Communications Group, Inc. (LaVoie Group), a firm
with a proven track record of building value for health science
innovations through...